Morgans feels EBR Systems has attained a key milestone by completing interim trial enrolment in SOLVE on time, which may lead to FDA submission by the first half of 2023.
The company has secured up to $50m in debt financing, which the broker sees as prudent. The target falls to $1.38 from $1.84 to reflect increased volatility and higher funding costs. The Speculative Buy rating is maintained.
Sector: Health Care Equipment & Services.
Target price is $1.38.Current Price is $0.53. Difference: $0.85 – (brackets indicate current price is over target). If EBR meets the Morgans target it will return approximately 62% (excluding dividends, fees and charges – negative figures indicate an expected loss).
